SBI Securities’s Adicet Bio ACET Stock Holding History

SBI Securities’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$250	Buy	35 +11	+46%	+$96	﹤0.01%	3337
2026 Q2	$207	Buy	24 +5	+26%	+$39	﹤0.01%	3313
2026 Q1	$129	Hold	19	–	–	﹤0.01%	3348
2025 Q4	$160	Sell	19 -33	-63%	-$365	﹤0.01%	3281
2025 Q3	$670	Buy	52 +1	+2%	+$12	﹤0.01%	2857
2025 Q2	$501	Buy	51 +3	+6%	+$32	﹤0.01%	2965
2025 Q1	$577	Buy	48 +37	+336%	+$529	﹤0.01%	2812
2024 Q4	$165	Buy	+11	New	+$208	﹤0.01%	3305

Other funds holding ACET

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SBI Securities's ACET Position: Q3 2026 in Review

SBI Securities increased its Adicet Bio (ACET) stake by 46% in Q3 2026, buying an estimated $96 and bringing the position to 35 shares worth $250. The position accounts for ﹤0.01% of the portfolio, ranked #3337.

SBI Securities first reported a position in ACET in Q4 2024 and has held it in 8 quarters since. The position peaked at $670 in Q3 2025. 3 funds tracked by Wall St. Rank hold ACET as of Q3 2026.

SBI Securities held 35 shares of Adicet Bio worth $250 as of Q3 2026.
SBI Securities bought 11 Adicet Bio shares in Q3 2026, an estimated $96.
Adicet Bio made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3337 holding.
SBI Securities first reported a position in Adicet Bio in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Adicet Bio position peaked at $670 in Q3 2025.
3 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.